ArticleThe Journal of biological chemistry2026
Analysis of ligand recognition by choline O-acetyltransferase reveals thiol-reactive assay interference and weak ligand affinity in solution.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choline O-acetyltransferase (ChAT) catalyzes the biosynthesis of acetylcholine and is a cysteine-rich enzyme that has been investigated using a range of biochemical, biophysical and structural approaches. Existing ChAT ligands rely on electrophilic or unstable scaffolds that limit their suitability for biological systems. Prior work established that arylvinylpyridiniums (AVPs) are substrate mimics that undergo ChAT-catalyzed hydrothiolation with CoA to form covalent AVP-CoA adducts. Here, we applied a structure-guided strategy to design nonreactive ligands intended to mimic key features of the AVP-CoA binding pose while avoiding covalent reactivity. Nineteen analogs were synthesized and evaluated across complementary biochemical, structural, and biophysical assays. X-ray crystallography confirmed that the new ligands bind within the ChAT tunnel similar to AVP-CoAs. Importantly, the high cysteine content of ChAT, especially within a reactive CXCXXC motif, rendered the enzyme susceptible to modification by the widely used 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) reagent used for measuring ChAT activity, leading to confounding results in thiol-dependent activity assays. Enzyme-free counter-screens demonstrated that all apparent inhibitory activity arose from interference with assay readout rather than true enzymatic inhibition. Surface plasmon resonance measurements established that none of the designed ligands display detectable reversible affinity for ChAT, despite their crystallographically validated poses, and no selectivity over the related enzyme carnitine O-acetyltransferase (CrAT) was observed. These findings demonstrate that confirmed binding with X-ray crystallography is insufficient to establish functional interaction with ChAT and highlight the susceptibility of this enzyme to thiol-reactive assay artefacts. More broadly, this work underscores the necessity of integrating orthogonal biophysical validation when studying ligand binding to cysteine-rich enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.